| 9.5 0 (0%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Kadmon Holdings operates as a biopharmaceutical firm, focusing on the discovery, development, and commercialization of small molecule compounds and biologics, primarily to address inflammatory and fibrotic disorders. Its leading therapeutic asset is KD025, an orally administered selective inhibitor of rho-associated coiled-coil kinase 2 (ROCK2), which is currently undergoing Phase II clinical evaluation for chronic graft-versus-host disease and various fibrotic conditions. Another key oral ROCK inhibitor, KD045, is also in development for fibrotic diseases. Additionally, the company is advancing KD033, an anti-PD-L1/IL-15 fusion protein, for oncological applications. Kadmon's broader pipeline encompasses Tesevatinib for autosomal dominant polycystic kidney disease; ribavirin, a nucleoside inhibitor, targeting hepatitis; and CLOVIQUE (trientine hydrochloride capsules) for the management of Wilson's disease. The company has established strategic partnerships and licensing agreements with entities like Nano Terra, Inc. and Dyax Corp. Established in 2010, Kadmon Holdings, Inc. maintains its headquarters in New York, New York.
Thu, 24 Apr 2025
KDMN Stock Price, News & Analysis - Stock Titan
Fri, 24 Jan 2025
Kadmon Announces Pricing of $200 Million Convertible Senior Notes Offering with 100% Capped Call Transactions - ACCESS Newswire
Wed, 23 Aug 2023
Treacy Gaffney Net Worth (2026) - GuruFocus
Wed, 01 Mar 2023
Steven Meehan Net Worth (2026) - GuruFocus
Wed, 08 Sep 2021
Meme Stock Movers for 9/8: Meta Materials, Nio, Support.com, Vinco Ventures and More - 24/7 Wall St.
Wed, 08 Sep 2021
Sanofi to acquire Kadmon to further strengthen growth of transplant business - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|